Literature DB >> 26597876

Renal function is impaired in normotensive chronic HCV patients: role of insulin resistance.

Angela Sciacqua1, Maria Perticone2, Eliezer J Tassone1, Antonio Cimellaro1, Benedetto Caroleo1, Sofia Miceli1, Michele Andreucci3, Anna Licata4, Giorgio Sesti1, Francesco Perticone5.   

Abstract

Renal dysfunction is an independent predictor for cardiovascular morbidity and mortality. We investigated whether chronic hepatitis C virus (HCV) infection and the related insulin resistance/hyperinsulinemia influence renal function in comparison with a group of healthy subjects and with another group with metabolic syndrome. We enrolled 130 newly diagnosed HCV outpatients matched for age and gender with 130 patients with metabolic syndrome and 130 healthy subjects. Renal function was evaluated by calculation of glomerular filtration rate (e-GFR, mL/min/1.73 m(2)) using the CKD-EPI equation. The following laboratory parameters were measured: fasting plasma glucose and insulin, total, LDL- and HDL-cholesterol, triglyceride, creatinine, and HOMA to evaluate insulin sensitivity. HCV patients with respect to both healthy subjects and metabolic syndrome patients have a decreased e-GFR: 86.6 ± 16.1 vs 120.2 ± 23.1 mL/min/1.73 m(2) (P < 0.0001) and 94.9 ± 22.6 mL/min/1.73 m(2) (P = 0.003), respectively. Regarding biochemical variables, HCV patients, in comparison with healthy subjects, have a higher triglyceride level, creatinine, fasting insulin and HOMA (3.4 ± 1.4 vs 2.6 ± 1.3; P < 0.0001). At linear regression analysis, the correlation between e-GFR and HOMA is similar in the metabolic syndrome (r = -0.555, P < 0.0001) and HCV (r = -0.527, P < 0.0001) groups. At multiple regression analysis, HOMA is the major determinant of e-GFR in both groups, accounting for, respectively, 30.8 and 27.8 % of its variation in the metabolic syndrome and HCV. In conclusion, we demonstrate that HCV patients have a significant reduction of e-GFR and that insulin resistance is the major predictor of renal dysfunction.

Entities:  

Keywords:  Cardiovascular risk; Chronic C hepatitis; Insulin resistance; Metabolic syndrome; Renal function

Mesh:

Substances:

Year:  2015        PMID: 26597876     DOI: 10.1007/s11739-015-1349-7

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  33 in total

1.  Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance.

Authors:  Giorgio Sesti; Angela Sciacqua; Marina Cardellini; Maria Adelaide Marini; Raffaele Maio; Marco Vatrano; Elena Succurro; Renato Lauro; Massimo Federici; Francesco Perticone
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

2.  Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group.

Authors:  K M Thrailkill; T Quattrin; L Baker; J E Kuntze; P G Compton; P M Martha
Journal:  Diabetes Care       Date:  1999-04       Impact factor: 19.112

3.  Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure.

Authors:  A Vijayan; S C Franklin; T Behrend; M R Hammerman; S B Miller
Journal:  Am J Physiol       Date:  1999-04

4.  Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals.

Authors:  Linda F Fried; Michael G Shlipak; Casey Crump; Anthony J Bleyer; John S Gottdiener; Richard A Kronmal; Lewis H Kuller; Anne B Newman
Journal:  J Am Coll Cardiol       Date:  2003-04-16       Impact factor: 24.094

5.  Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection.

Authors:  Sanjaya Kumar Satapathy; Chandra Sekhar Lingisetty; Susan Williams
Journal:  Hepatol Int       Date:  2011-06-23       Impact factor: 6.047

6.  Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study.

Authors:  Manjinder S Sandhu; Adrian H Heald; J Martin Gibson; J Kennedy Cruickshank; David B Dunger; Nicholas J Wareham
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

7.  Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C.

Authors:  Giovanni Targher; Lorenzo Bertolini; Roberto Padovani; Stefano Rodella; Guido Arcaro; Christopher Day
Journal:  J Hepatol       Date:  2007-02-15       Impact factor: 25.083

8.  Association of hepatitis C virus infection with prevalence and development of kidney disease.

Authors:  Sharon M Moe; A J Pampalone; Susan Ofner; Marc Rosenman; Evgenia Teal; Siu L Hui
Journal:  Am J Kidney Dis       Date:  2008-04-28       Impact factor: 8.860

9.  Hepatitis C virus infection and the risk of coronary disease.

Authors:  Adeel A Butt; Wang Xiaoqiang; Matthew Budoff; David Leaf; Lewis H Kuller; Amy C Justice
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

10.  Insulin-like growth factor-1 and glomerular filtration rate in hypertensive patients.

Authors:  Francesco Perticone; Raffaele Maio; Angela Sciacqua; Maria Perticone; Irma Laino; Sofia Miceli; Debora Mazzaferro; Alessandra Pascale; Francesco Andreozzi
Journal:  J Hypertens       Date:  2009-03       Impact factor: 4.844

View more
  3 in total

1.  Genetic Polymorphism of CYP27B1-1260 as Associated With Impaired Fasting Glucose in Patients With Chronic Hepatitis C Undergoing Antiviral Therapy.

Authors:  Derong Sun; Wenqian Qi; Song Wang; Xu Wang; Yonggui Zhang; Jiangbin Wang
Journal:  Hepat Mon       Date:  2016-05-28       Impact factor: 0.660

2.  Usefulness of metabolic score for insulin resistance index in estimating the risk of mildly reduced estimate glomerular filtration rate: a cross-sectional study of rural population in China.

Authors:  Pengbo Wang; Qiyu Li; Xiaofan Guo; Ying Zhou; Zhao Li; Hongmei Yang; Shasha Yu; Guozhe Sun; Liqiang Zheng; Yingxian Sun; Xingang Zhang
Journal:  BMJ Open       Date:  2021-12-16       Impact factor: 2.692

Review 3.  Hepatitis C virus infection in chronic kidney disease: paradigm shift in management.

Authors:  So Mi Kim; Il Han Song
Journal:  Korean J Intern Med       Date:  2018-06-28       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.